Pharmacotherapy 37 , 927943 (2017)
The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
FDA's April 2026 proposal to remove semaglutide and tirzepatide from the 503B bulks list - with a public comment period through June 2026 - creates a genuine decision window: buyers who enroll now are committing to a subscription before the outcome of that proposal is known
Taking this via a recommended enteric coated supplement (Vital Nutrients GLP-1 Complete and Pendulum Akkermansia) can help repopulate the gut and does not require lifelong supplementation
Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity, again the same drug under different names
Medications like orforglipron (an oral, non-peptide GLP-1 agonist), survodutide (a dual glucagon/GLP-1 agonist), and CagriSema (combining cagrilintide with semaglutide) are advancing through clinical trials